CYP17 & SULT1A1 gene polymorphisms in Indian breast cancer

被引：26

作者：

Chacko P. ^{[1
]}

Rajan B. ^{[2
]}

Mathew B.S. ^{[2
]}

Joseph T. ^{[1
]}

Pillai M.R. ^{[1
]}

机构：

[1] Division of Molecular Medicine, Drug Development and Chemoinformatics, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala State

[2] Breast Specialty Clinic, Regional Cancer Centre, Thiruvananthapuram

来源：

Breast Cancer | 2004年 / 11卷 / 4期

关键词：

Breast cancer; CYP17; MspAl; Polymorphism; SULT1A1;

D O I：

10.1007/BF02968046

中图分类号：

学科分类号：

摘要：

Background: Breast cancer is the most common cancer among women worldwide. Life-time exposure to steroid hormones, especially estrogen, is a major risk factor for breast cancer. Functional polymorphisms in genes encoding steroid metabolizing enzymes may thus be important as biomarkers of individual susceptibility to breast cancer. The CYP17 and SULT1A1 genes encode for two enzymes involved in hormone biosynthesis and metabolism. Single nucleotide polymorphisms of these genes may result in inter-individual variability in steroid hormone biosynthesis and metabolism thus influence the development of breast cancer. Methods: We tested this hypothesis by conducting a case - control study on a group of 140 breast cancer cases and 140 healthy age-matched controls. Analysis of CYP17 & SULT1A1 genotypes were done by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Results: The genetic polymorphisms of the estrogen-related genes SULT1A1 (OR = 2.5, 95% CI = 1.28-4.98) and CYP17 (OR = 4.1, 95% CI = 1.78-9.63) were associated with an increased risk of breast cancer among postmenopausal women. Our data also showed evidence for the genetic regulation of serum 17β estradiol (E2) levels as measured by ELISA among the premenopausal women with a significant increase in the serum E2 level for the CYP17 A2 variants. Conclusion: These results suggest that both CYP17 and SULT1A1 genotypes could be important determinants of breast cancer risk in Indian women and may help in early identification of high risk subjects. Such genotype analysis resulting in a high-risk profile holds considerable promise for individualizing screening, diagnosis and therapeutic intervention in breast cancer.

引用

页码：380 / 388

页数：8

共 32 条

[21]

Dunning A.M., Healey C.S., Pharoah P.D.P., Foster N.A., Lipscombe J.M., Redman K.L., Easton D.F., Day N.E., Ponder B.A.J., No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer, British Journal of Cancer, 77, 11, pp. 2045-2047, (1998)

[22]

Helzlsouer K.J., Huang H.-Y., Strickland P.T., Hoffman S., Alberg A.J., Comstock G.W., Bell D.A., Association between CYP17 polymorphisms and the development of breast cancer, Cancer Epidemiology Biomarkers and Prevention, 7, 10, pp. 945-949, (1998)

[23]

Young I.E., Kurian K.M., Annink C., Kunkler I.H., Anderson V.A., Cohen B.B., Hooper M.L., Wyllie A.H., Steel C.M., A polymorphism in the CYP17 gene is associated with male breast cancer, British Journal of Cancer, 81, 1, pp. 141-143, (1999)

[24]

Habuchi T., Liqing Z., Suzuki T., Sasaki R., Tsuchiya N., Tachiki H., Shimoda N., Satoh S., Sato K., Kakehi Y., Kamoto T., Ogawa O., Kato T., Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect, Cancer Res, 60, pp. 5710-5713, (2000)

[25]

Kittles R.A., Panguluri R.K., Chen W., Massac A., Ahaghotu C., Jackson A., Ukoli F., Adams-Campbell L., Isaacs W., Dunston G.M., CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans, Cancer Epidemiology Biomarkers and Prevention, 10, 9, pp. 943-947, (2001)

[26]

Diamanti-Kandarakis E., Bartzis M.I., Zapanti E.D., Spina G.G., Filandra F.A., Tsianateli T.C., Bergiele A.T., Kouli C.R., Polymorphism TRC C (-34 bp) of gene CYP17 promoter in greek patients with polycystic ovary syndrome, Fertility and Sterility, 71, 3, pp. 431-435, (1999)

[27]

Kristensen V.N., Haraldsen E.K., Anderson K.B., Lonning P.E., Erikstein B., Karesen R., Gabrielsen O.S., Borresen-Dale A.-L., CYP17 and breast cancer risk: The polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1, Cancer Research, 59, 12, pp. 2825-2828, (1999)

[28]

Nagaya N., Toi M., Sunahara S., Kurimoto F., Tominaga T., Determination of intratumoral estrone (E <sub>1</sub>) and estradiol (E <sub>2</sub>) in primary breast cancer tissues by sensitive HPLC-RIA, Japanese Journal of Cancer and Chemotherapy, 24, 3, pp. 329-336, (1997)

[29]

Carlini E.J., Raftogianis R.B., Wood T.C., Jin F., Zheng W., Rebbeck T.R., Weinshilboum R.M., Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects, Pharmacogenetics, 11, 1, pp. 57-68, (2001)

[30]

Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., Shen C.Y., Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: A multigenic study on cancer susceptibility, Cancer Res, 59, pp. 4870-4875, (1999)

← 1 2 3 4 →